The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts

Biochemical Pharmacology

Volumn 62, Issue 12, 2001, Pages 1675-1684

  Stiborová, Marie ^a   Bieler, Christian A ^b   Wiessler, Manfred ^b   Frei, Eva ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

32P postlabeling; Activation; Anticancer drug; Cytochrome P450; DNA adduct; Ellipticine

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DIETHYLDITHIOCARBAMIC ACID; ELLIPTICINE; FURAFYLLINE; PHOSPHORUS 32; QUINIDINE; RECOMBINANT ENZYME; SULFAPHENAZOLE; TRITIUM; TROLEANDOMYCIN;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DNA ADDUCT; DNA MODIFICATION; DRUG DNA BINDING; DRUG MECHANISM; DRUG SPECIFICITY; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RAT; SWINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DNA; DNA ADDUCTS; ELLIPTICINES; HUMANS; ISOENZYMES; MICROSOMES, LIVER; RABBITS; RATS;

EID: 0035894174     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(01)00806-1     Document Type: Article

References (67)

1. Synthesis of the tumor-inhibitory alkaloids, ellipticine, 9-methoxyellipticine, and related pyrido-[4,3-b]carbazoles
2. Phase II study of ellipticinium in advanced breast cancer
3. Data of pre-clinical and early clinical trials of acriflavine and hydroxy-methyl-ellipticine reviewed, enriched by the experience of their use for 18 months to 6 years in combination with other HIV1 virostatic
4. Status of the NCI preclinical antitumor drug discovery screen: Implications for selection of new agents for clinical trials
5. The future of drug development
6. Anticancer specificity of some ellipticinium salts against human brain tumors in vitro
7. Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs to treatment of human brain tumor xenografts
8. Synthesis and binding properties to DNA and to opioid receptor of enkephalin-ellipticinium conjugates
9. Attempts to target antitumor drugs towards opioid receptor-rich mouse tumor cells with enkephalin-ellipticinium conjugates
10. Design, synthesis, and biological evaluation of ellipticine-estradiol conjugates
11. Cytotoxic agents directed to peptide hormone receptors: Defining the requirements for a successful drug
12. Multimodal action of antitumor agents on DNA: The ellipticine series
13. Influence of inducers of monooxygenases on the cytotoxic efficiency of ellipticine on leukemic L1210 cells
14. Ellipticines and human liver microsomesspectral interaction with cytochrome P-450 and hydroxylation. Inhibition of arylhydrocarbon metabolism and mutagenicity
15. Molecular analysis of mutations induced by the intercalating agent ellipticine at the hisD3052 allele of Salmonella typhimurium TA98
16. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2
17. Analysis of structural requirements for Ah receptor antagonist activity: Ellipticines, flavones, and related compounds
18. Constitutive activation of the aromatic hydrocarbon receptor
19. Mutagenicity and cytotoxicity of five antitumor ellipticines in mammalian cells and their structure-activity relationships in Salmonella
20. Mutagenicity of topoisomerase-active agents in bacteriphage T4
21. Tests for the genotoxicity of m-AMSA, etoposide, teniposide and ellipticine in Neurospora crassa
22. Mutagenic responses of thirteen anticancer drugs on mutation induction at multiple genetic loci and on sister chromatic exchanges in Chinese hamster ovary cells
23. Comparison of the mutagenic responses of 12 anticancer drugs at the hypoxanthine-guanine phosphoribosyl transferase and adenosine kinase loci in Chinese hamster ovary cells
24. Biochemical prophage induction assay: A rapid test for antitumor agents that interact with DNA
25. Prophage induction by DNA topoisomerase II poisons and reactive oxygen species: Role of DNA breaks
26. High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine
27. Ellipticine increases the superhelical density of intracellular SV40 DNA by intercalation
28. DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives
29. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: Structure-activity relationships
30. Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy
31. Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: A possible anticancer mechanism
32. Protonophoric activity of ellipticine and isomers across the energy-transducing membrane of mitochondria
33. Expression of xenobiotic metabolizing enzymes in breast cancer
34. Cytochrome P450 expression in tumors
35. Antitumor prodrug development using cytochrome P450 (CYP) mediated activation
36. 13C NMR spectroscopy
37. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy
38. 32P-post-labeling: Evidence for reductive activation by peroxidases
39. 32P-postlabeling of DNA adducts derived from peroxidative activation of carcinogenic non-aminoazo dye 1-phenylazo-2-hydroxynaphthalene (Sudan I)
40. Presence and activity of cytochrome P450 isoforms in minipig liver microsomes. Comparison with human liver samples
41. Investigation of the bicinchoninic acid protein assay: Identification of the groups responsible for color formation
42. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature
43. Dealkylation of pentoxyresorufin: A rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat
44. Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes
45. Properties of electrophoretically homogeneous phenobarbital-inducible and beta-naphthoflavone-inducible forms of liver microsomal cytochrome P-450
46. Metabolism of nitrosamines by purified rabbit liver cytochrome P-450 isozymes
47. Purification to homogeneity and characterization of a form of cytochrome P-450 with high specificity for benzo[a]pyrene from β-naphthoflavone-pretreated rat liver microsomes
48. NADPH-cytochrome c (P450) reductase: Spectrophotometric and stopped flow kinetic studies on the formation of reduced flavoprotein intermediates
49. Ethoxy-, pentoxy-, and benzyloxyphenoxazones, and homologues: A series of substrates to distinguish between different induced cytochromes P-450
50. Benzenediazonium ion derived from Sudan I forms an 8-(phenylazo)guanine adduct in DNA
51. Mechanism of formation and structural characterization of DNA adducts derived from peroxidative activation of benzidine
52. New selective inhibitors of cytochrome P450 2B4 and an activator of cytochrome P450 3A6 in rabbit microsomes
53. 32P-postlabeling analysis of nonradioactive aromatic carcinogen-DNA adducts
54. 32P-postlabeling test for structurally diverse DNA adducts
55. 32P-adduct assay comparative recoveries of structurally diverse DNA adducts in the various enhancement procedures
56. DNA adduct formation of aristolochic acid I, and II in vitro, and in vivo
57. 32P-postlabeling analysis using different chromatographic procedures
58. 5
59. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors
60. Cooperativity in oxidation catalyzed by cytochrome P450 3A4
61. 2-methyl-9-hydroxyellipticinium to DNA in vitro
62. Covalent binding of elliptinium acetate (NSC 264137) to mucleic acids of L1210 cells in culture
63. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer
64. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells
65. Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics
66. Altered regulation of P-450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line